15.11.2018, 19:23
uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
~ All Patients Achieved and Sustained Therapeutic Factor IX Activity with a Mean FIX Level of 31% of Normal at Six Weeks After Administration ~
~ None of the Patients Received Factor Infusions, Experienced Any Reported Bleeding Events or Required Immunosuppression Over a Combined 24 Weeks of Observation ~
~ Company R&D Day Scheduled for Monday, November 19 at 8:30 a.m. EST ~
https://finance.yahoo.com/news/uniqure-a...ccounter=1
![[Bild: QUREc1dl1221.png]](https://finviz.com/publish/111518/QUREc1dl1221.png)
QURE +48 %
~ All Patients Achieved and Sustained Therapeutic Factor IX Activity with a Mean FIX Level of 31% of Normal at Six Weeks After Administration ~
~ None of the Patients Received Factor Infusions, Experienced Any Reported Bleeding Events or Required Immunosuppression Over a Combined 24 Weeks of Observation ~
~ Company R&D Day Scheduled for Monday, November 19 at 8:30 a.m. EST ~
https://finance.yahoo.com/news/uniqure-a...ccounter=1
QURE +48 %
![[Bild: QUREc1dl1302.png]](https://finviz.com/publish/022719/QUREc1dl1302.png)